Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MiNK Therapeutics ( (INKT) ) has provided an announcement.
On July 11, 2005, MiNK Therapeutics announced a significant achievement in its clinical trial for agenT-797, an allogeneic iNKT cell therapy, which resulted in complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer. Additionally, at the 2025 AACR Immuno-Oncology meeting, MiNK presented promising data from its Phase 2 trial in second-line gastric cancer, showing immune activation and extended survival, with ongoing enrollment and future readouts expected.
The most recent analyst rating on (INKT) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.
Spark’s Take on INKT Stock
According to Spark, TipRanks’ AI Analyst, INKT is a Underperform.
MiNK Therapeutics’ overall stock score reflects significant financial challenges and negative market sentiment. The company’s ongoing losses, reliance on external financing, and technical indicators pointing to potential downward momentum weigh heavily on the score. Despite promising clinical advancements and strategic partnerships, financial instability and valuation challenges remain primary concerns.
To see Spark’s full report on INKT stock, click here.
More about MiNK Therapeutics
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies.
Average Trading Volume: 805,159
Technical Sentiment Signal: Buy
Current Market Cap: $255.8M
Learn more about INKT stock on TipRanks’ Stock Analysis page.